m6A modification as a potential therapeutic target for autoimmune diseases

FHS
July 15, 2023
12:17 am

N6-methyladenosine (m6A) is the most extensive studied RNA modification across various species, and the important effect of m6A modification in immune system has been revealed in distinct contexts, including mRNA metabolism, cell differentiation, proliferation and response to stimulation.

New zwitterionic polyion developed for effective plasmid DNA delivery in muscle cells

Researchers from Tokyo Metropolitan University have created a new drug delivering molecule, a zwitterionic polymer complex that can help get plasmid DNA inside cells when

July 29, 2024

New report highlights how telehealth has transformed the access to care across Michigan

In just three years, millions of people across Michigan’s two huge peninsulas have taken advantage of their newfound ability to connect with their doctors, nurses

July 22, 2023

Cellusion shares pipeline update for eye disease stem cell therapy – Pharmaceutical Technology

Keratoconus of eye, 4th degree. Credit: Garna Zarina via Shutterstock Cellusion plans to begin a Phase I/II trial for its bullous keratopathy candidate CSL-001 in

June 28, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.